A method to assess the dissipation of residual hypnotics: eszopiclone versus zopiclone. by Boyle, J et al.
  
1 
A method to assess the dissipation of the effects of residual hypnotics: Eszopiclone versus 
Zopiclone. 
Julia Boyle (PhD),1 John A. Groeger (PhD),2,3 Walter Paska (PhD),4 James A. Cooper (PhD),5 
Carol Rockett (PharmD),6 Sion Jones (PhD),4 Paul Gandhi (Mrcpsych),5 Jenny Scott (MSc),4 
Giuseppe Atzori (MSc)1,Derk-Jan Dijk (PhD)1,3  
1Surrey Clinical Research Centre, Faculty of Health & Medical Sciences, University of Surrey, 
Guildford, Surrey, UK 
2Department of Applied Psychology, University College Cork, Ireland 
3Surrey Sleep Research Centre, Faculty of Health & Medical Sciences, University of Surrey, 
Guildford, Surrey, UK 
4GlaxoSmithKline, Stockley Park, Uxbridge, Middlesex, UK  
5GlaxoSmithKline, Brentford, Middlesex, UK 
6GlaxoSmithKline, Research Triangle Park, N.C., USA 
Corresponding author: Julia Boyle BSc (Hons) PhD 
Director of Surrey CRC 
Division of Clinical Medicine 
Faculty of Health & Medical Sciences 
University of Surrey 
Guildford 
Surrey 
GU2 7XP 
J.Boyle@surrey.ac.uk 
Tel +44 (0)1483 689783 
Fax +44 (0)1483 689790 
 
Conflicts of Interest and Source of funding: Julia Boyle has received research support from 
GlaxoSmithKline, Merck&Co Inc and Pfizer Ltd.  
John A. Groeger has received research support from GlaxoSmithKline, H Lundbeck A/S, Merck 
& Co Inc and has served as consultant for Glaxo-Smith Kline, H Lundbeck A/S, Merck&Co Inc.     
Derk-Jan Dijk has received research support from GlaxoSmithKline, H Lundbeck A/S, 
Merck&Co Inc, Philips Lighting, Organon, Takeda, Wellcome Trust and has served as consultant 
  
2 
for Actelion, Cephalon, Glaxo-Smith Kline, Lilly, H Lundbeck A/S, Merck&Co Inc., Metronaps, 
Ono Pharmaceuticals, Pfizer Inc, Philips Lighting, Sanofi Aventis, Takeda.  
James Cooper, Carol Rockett, Paul Gandhi, Sion Jones and Jenny Scott, are employees of 
GlaxoSmithKline.  
Walter Paska was an employee of GSK at the time of study conduct.  
For the remaining authors none were declared. 
Scientists and biostatisticians at GlaxoSmithKline, which sponsored the study, described in this 
manuscript, collaborated with study investigators in study design, data analysis, interpretation of 
the results, preparation of the manuscript, and the decision to submit the manuscript for 
publication.  Statistical analyses were conducted at GlaxoSmithKline. 
Running title: Eszopiclone next-day impairment profile. 
Funding: The study was funded by GlaxoSmithKline. 
  
3 
Abstract  
Next-day residual effects of single evening doses of 3 mg eszopiclone, 7.5 mg zopiclone and 
placebo were assessed in a randomised, double-blind, placebo-controlled, 3-way crossover study, 
that used a mild sleep restriction protocol (sleep duration 7 hours). During each period, 91 
healthy volunteers spent 2 consecutive nights in the laboratory with time in bed restricted to 7 
hours. Volunteers completed the Continuous Tracking Test, Critical Flicker Fusion task, Digit 
Symbol Substitution Test, N-back tasks, and Linear Analogue Rating Scales every half-hour from 
7.5 to11.5 hours post-dose commencing 15 min after awakening. Night-time dosing of both 
eszopiclone (3 mg) and racemic zopiclone (7.5 mg) was associated with next-day performance 
impairment and these residual effects dissipated over time.  Eszopiclone did not differ from 
zopiclone on the primary endpoint, mean CTT tracking error averaged from 7.5-9.5 hours post-
dose, however a pre-specified post hoc parametric analysis of reciprocal-transformed data 
favoured eszopiclone over racemic zopiclone (P=0.026).  
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 Introduction 
The adverse personal and economic consequences of insomnia, which affects an 
estimated 1 in 5 adults worldwide 1, are well established 2. There is consistent evidence that 
insomnia is often coexistent with psychiatric disorders such as depression and anxiety 3, as well 
as emerging evidence that a bidirectional relationship may exist 4. 
 
Insomnia is treated primarily with hypnotics that, while generally well tolerated, can be 
associated with side effects potentially as detrimental as insomnia itself. In particular, residual 
sedation (the “hangover” effect), which constitutes prolongation of the drugs’ hypnotic effect, 
results in daytime sleepiness, impairment of psychomotor and cognitive functioning 5 and 
increased risk of injury and accidents 6. 
 
The two compounds under investigation, zopiclone and eszopiclone, are non-benzodiazepine 
hypnotics prescribed in the treatment of both transient and short-term insomnia and often for its 
chronic variant.  Zopiclone, a cyclopyrrolone class racemic mixture of two steroisomers of which 
only one is active, was introduced in the second half of the eighties and has been proven to be an 
effective hypnotic, it has however been shown to impair next-day functioning 7.  
 
The single-isomer hypnotic eszopiclone [(S)-zopiclone] is a short-acting non-benzodiazepine 
insomnia medication. As the active isomer of racemic zopiclone, eszopiclone is effective at less 
than half the dose of racemic zopiclone 8.  In addition, exposure to eszopiclone 3.5 mg, a similar 
concentration of the (S)-isomer contained in 7.5 mg  zopiclone, has an earlier time to peak 
concentration (Tmax 1.0 hr compared with racemic zopiclone 1.5 hr), and significantly less 
exposure to active metabolites,  which may explain  the difference of the two compounds on their 
residual effect profile 9.  
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The pharmacokinetic profile of eszopiclone, therefore could potentially reduce residual-effects, 
and in randomised, double-blind, placebo-controlled studies in healthy volunteers and patients 
with primary insomnia, cognitive function and psychomotor function were not impaired the 
morning after 3 mg eszopiclone compared with placebo 10. However, whilst a proportion of 
patient studies have reported improved subjective ratings of daytime alertness, there was 
evidence that, subjective daytime alertness and ability to function was reduced at the 3mg dose 11. 
 
Eszopiclone has been compared with placebo in studies of next-day residual effects.  However, it 
has not been previously compared with racemic zopiclone in a head-to-head study evaluating 
next-day psychomotor and cognitive effects. The study reported herein was conducted to 
compare the effects of a single bedtime dose of eszopiclone (3 mg) on next-day psychomotor and 
cognitive function with those of zopiclone (7.5 mg) and placebo in healthy volunteers. Unlike 
previous studies of residual effects, which assessed for impairment after at least 8 hours of 
sleep10, the present study used a sleep-restriction protocol that limited sleep duration to 7 hours in 
order to approximate real-life circumstances 12. The dissipation of residual effects after the sleep 
episode was assessed with high temporal resolution (at half hourly intervals) from 15 minutes to 
255 minutes after wake time to include the period characterized by sleep inertia during which 
residual effects are expected to be most evident 13.    
 
Materials and Methods 
Participants 
Medical and psychiatric history; physical examination and serum chemistry, hematology, and 
urinalysis results determined the inclusion of 25 to 40-years old participants of both sexes who 
had provided informed written consent.  Exclusion criteria included pregnancy, lactation, 
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ineffective contraception; signs and symptoms of a sleep disorder or irregularity; weight <50 kg 
or BMI <18 or >30; history of substance abuse or dependence; smoking >5 cigarettes/day; 
consuming >300 mg xanthinated products or more than 3 to 4 units (men) or 2 to 3 units 
(women) of alcohol (UK government guidelines; daily units); use of prescription or OTC 
psychotropic medications (excluding the occasional use of some cold, flu, or allergy remedies 
containing antihistamines and opiates) in the 3 months before screening; and any other 
medication within 2 weeks before screening. A wrist-mounted actigraphy device (Actiwatch AW, 
CamNtech Ltd, Camdridge UK) aided assessment of ongoing eligibility throughout screening, 
treatment sessions, and washout periods. Further, alcohol breath tests and urine tests for drugs of 
abuse were administered throughout the study to ensure compliance.  
 
Procedures 
This was a randomised, double-blind, double-dummy, placebo-controlled, 3-way crossover study 
(GlaxoSmithKline protocol ESZ111503) , comparing  a single bedtime dose of 3 mg of 
eszopiclone with 7.5 mg of  zopiclone and placebo relative to next-day psychomotor and 
cognitive function in healthy adults. The protocol was approved by an independent ethics 
committee (Brent Medical Ethics Committee, Harrow, UK). The study was conducted at a single 
UK site in accordance with "good clinical practice" (GCP); the European Union clinical trials 
directive, 2004; and the guiding principles of the Declaration of Helsinki. The study was 
registered with clinicaltrials.gov, identifier: NCT00699608. 
  
The 7- to - 28 day screening period included a clinical visit and 1-night polysomnography (PSG) 
recording. Upon satisfactory eligibility criteria participants returned to the clinic after a further 2 
to 21 days and were randomised in balanced order to 3 crossover treatment sessions during which 
they received 3 mg eszopiclone, 7.5 mg zopiclone, or placebo (1 randomised treatment in each 
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crossover session). Each treatment session comprised two consecutive days of admission to the 
study clinic for completion of multiple next-day assessments of psychomotor and cognitive 
function following dosing at 10:45 PM with single-blind placebo on Night 1 and double-blind 
study medication on Night 2. Next-day assessments were completed on Day 2 (baseline) and Day 
3 (post-treatment), respectively. Lights-out was at 11:00 PM, and sleep time was restricted to 7 
hours (11:00 PM to 6:00 AM) in order to approximate real-life circumstances and to assess the 
time course of residual effects. A safety follow-up visit was scheduled 7±1 days after the last 
treatment session. 
 
Measures  
Cognitive and psychomotor measures included: Continuous Tracking Test (CTT) 14, Critical 
Flicker Fusion (CFF) 15, DSST 16, N-backs (1-back and 3-back) 17, and Linear Analogue Rating 
Scales (LARS) 18. Testing commenced at 06:15, 15 minutes after awakening (7.5 hours post-
dose). The primary comparison of interest was the difference between eszopiclone 3 mg and 
zopiclone 7.5 mg on the CTT mean tracking error averaged over 5 assessments:  7.5, 8, 8.5, 9, 
and 9.5 hours postdose. Secondary endpoints were assessed in the morning at 7.5, 8, 8.5, 9, 9.5, 
10, 10.5, 11, and 11.5 hours after double-blind dosing, including CTT mean tracking error and 
mean reaction time; CFF mean threshold frequency, DSST total of attempted substitutions and 
total of correct substitutions; N-back percentage of correct responses and reaction time; and 
LARS subjective estimates of sedation, mood and coordination. 
 
Data Analysis 
Data on psychomotor and cognitive test performance were analyzed for all participants who 
received at least 1 dose of double-blind study medication (Intention-to-treat, ITT population). 
Analyses of covariance (ANCOVA) techniques were used to analyse the primary and secondary 
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endpoints. The model for the primary endpoint included fixed-effect terms of participants’ 
baseline, adjusted period-specific baseline, age, gender, treatment, and period. Subject was 
included as a random effect. The individual time points were analysed using a repeated-measures 
model with interactions of time-point*treatment, time-point*subject level baseline, and time- 
point*period-specific baseline, in addition to the core covariates used in the primary model.  
Point estimates for the mean differences with corresponding 95% confidence intervals (CIs) were 
calculated. The associated P-values were provided for eszopiclone 3mg versus zopiclone 7.5mg 
as well as each treatment versus placebo. No adjustment for multiplicity was done. 
 
Error diagnostics from residuals were examined to ensure the assumptions of the model were 
valid. Assumptions of normality and homogeneity of variance underlying the ANCOVA model 
were violated, i.e. non-normal residuals and non-constant variance. Therefore transformations of 
the primary endpoint and nonparametric methods were applied to assess the robustness of the 
analysis. The ANCOVA model assumptions were violated for the N-back percentage of correct 
responses; therefore, a a priori rank transformation was applied to the data. 
To aid interpretation of the clinical relevance of the findings, a post hoc evaluation of 
standardised differences for the reciprocal-transformed and rank-transformed primary endpoint 
was performed. Post hoc evaluations of standardised differences were also completed for the 
secondary endpoints.  Standardised differences were calculated for three 1-hourly assessment 
phases corresponding to early morning (7.5 to 8.5 hours postdose), mid-morning (9 to 10 hours 
postdose), and late morning (10.5 to 11.5 hours postdose).  
 
Tolerability 
Tolerability was considered as the percentage of participants with adverse events (AE) or serious 
adverse events (SAE) during the double-blind treatment period, i.e. the time of receiving double-
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blind study medication on Night 2 until midnight of the next day, which was Day 3. This 
followed the European Medicine Authority definition for AE and SAE 19 Adverse-event data 
were summarised with descriptive statistics for the ITT population. Other safety measures 
included vital signs, clinical laboratory assessments, and physical examinations at the screening 
and follow-up visits as well as regular pregnancy testing. 
 
Results 
Sample 
Ninety-one participants were randomised to treatment and received at least 1 dose of double-
blind study medication. Four of the 91 participants prematurely withdrew from the study because 
of non-study commitments, 1 for the protocol violation of a positive alcohol-breath test, and 1 
because of AEs. Participants were White (69%); Black (15%), Asian (15%). Mean age was 29.8 
years (SD=3.9), and 51% were female. Mean BMI was 23.9 (SD=2.9).  
Primary Endpoint 
Primary Analysis 
Eszopiclone (3 mg) did not differ significantly from zopiclone (3.75 mg eszopiclone) on the 
primary endpoint, i.e. CTT mean tracking error; average of the first 5 assessments on Day 3, 
[eszopiclone (3 mg) versus zopiclone (7.5 mg) – 0.99 pixels, 95% CI – 2.74 to 0.76, P=0.267]. 
Both active treatments significantly differed from placebo (eszopiclone versus placebo: 2.20 
pixels, 95% CI 0.45 to 3.96, P=0.014; zopiclone versus placebo: 3.19 pixels, 95% CI 1.46 to 
4.93, P<0.001) (Figure 1). 
Post Hoc Analyses of the Primary Endpoint 
Parametric ANCOVA analysis of the reciprocal-transformed endpoint yielded a statistically 
significant difference favoring eszopiclone (3 mg) over zopiclone (3.75 mg eszopiclone; 
P=0.026) as well as statistically significant differences between each active treatment and 
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placebo (P<0.001). A nonparametric rank-transformed analysis yielded results consistent with the 
parametric reciprocal-transformed analysis, but the difference between eszopiclone and zopiclone 
did not reach statistical significance at the 5% level (P=0.061). In the post hoc analysis of 
standardised differences for the reciprocal-transformed and rank-transformed primary endpoint, 
small but potentially clinically relevant differences of 0.30 and 0.24, respectively, were observed 
in favour of eszopiclone over zopiclone.   
Secondary Endpoints 
The secondary endpoints (Figure 1] were broadly consistent with those for the primary endpoint. 
Numerical trends favoring eszopiclone over zopiclone were generally observed, but in the 
majority of cases fell short of statistical significance. The N-back test differentiated eszopiclone 
from zopiclone most clearly and consistently (Figure 2). Trends toward improvement in 
performance as time since waking increased were observed for the DSST number attempted and 
number correct, and LARS sedation (Figure 3). 
 
Post hoc analyses of standardised differences on the secondary endpoints, revealed small but 
potentially clinically relevant standardised differences (≥0.20) favouring eszopiclone (3mg) over 
zopiclone (3.75mg eszopiclone) for 7 of the 14 endpoints during the early phase of the morning 
(CTT mean tracking error, CTT reaction time, 1-back and 3-back percentage of correct 
responses, 3-back reaction time, LARS sedation, and LARS coordination); 1 of 14 endpoints 
during the middle phase (1-back percentage of correct responses), and 3 of 14 endpoints during 
the late phase of the morning (CTT mean tracking error, 3-back percentage of correct responses, 
and LARS sedation, Figure 3).  
 
 
Adverse Events 
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The proportion of participants with at least 1 AE was 50% with eszopiclone, 49% with zopiclone, 
and 13% with placebo. The most common AEs were dysgeusia and somnolence (Table 1). No 
SAEs were reported. One participant prematurely withdrew from the study because of AE. This 
participant, a 25-year-old female, reported feelings of fear and hallucinations, both events began 
26 minutes after a dose of eszopiclone in the second crossover period. The fear event lasted for 
39 minutes, and the hallucination event lasted for 6 minutes. Both events were of moderate 
severity. The investigator deemed these adverse events to be drug related. 
  
Discussion 
Next-day residual impairment constitutes a significant problem with many hypnotics. In 
experimental studies in healthy volunteers, hypnotics cause sedation and impair psychomotor 
function, attention, and memory the day after bedtime use 6 and in epidemiologic studies, 
hypnotics are associated with increased risk of traffic accidents 20. One of the outcomes of the 
development of eszopiclone was the assertion that the compound improved upon the next-day 
residual-effect profiles of other insomnia medications including its racemate parent zopiclone. To 
assess the veracity of this claim this randomised, double-blind, placebo-controlled head-to-head 
study compared eszopiclone (3 mg) with zopiclone (3.75 mg eszopiclone) in a protocol designed 
to quantify the time course of residual effects after mild sleep restriction in healthy volunteers, 
i.e.7 hours of time in bed for 2 consecutive nights.  
 
Compared with placebo, both eszopiclone (3 mg) and zopiclone (3.75 mg eszopiclone) were 
associated with next-day residual effects that were most severe shortly after awakening , 
dissipated over time but remained significant for several hours after awakening. Some 
differentiation between the compounds was observed, in particular for tasks that had a high 
demand on executive resources (3-back) rather than the less demanding tasks of sensori-motor 
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performance. Interestingly there were indications of smaller residual effects with eszopiclone (3 
mg) compared with  zopiclone (3.75 mg eszopiclone) across a range of tests including the CTT, 
DSST, the N-back  (1- and 3-back), and the LARS (sedation and coordination scores). 
 
The difference between eszopiclone (3 mg) and zopiclone (7.5 mg) was not statistically 
significant on the primary endpoint. Transformation of the primary endpoint and ranked analysis 
in accordance with a priori stipulations, demonstrated differences between eszopiclone and 
zopiclone that were either statistically significant or approached statistical significance in favour 
of eszopiclone, however both compounds differed significantly form placebo. Previous studies in 
patients with primary and coexistent insomnia have shown that eszopiclone was consistently 
associated with improvements in daytime functioning, subjective alertness and health-related 
quality of life 21, 7. Also a study with healthy participants and primary insomnia patients using a 
comprehensive battery of psychometric tests and car driving ability did not demonstrate residual 
impairment, however testing for residual impairment did not begin earlier than 9.75 hr post-dose 
13
. The mild sleep restriction protocol used in this study proved an effective tool for 
demonstrating residual impairment.  Time constraints limited the number of cognitive 
assessments that could be made and did not allow inclusion of vigilance type tests, such as the 
psychomotor vigilance task. 
 
This study is, to the authors’ knowledge, the first well-controlled study attempting to characterise 
thoroughly the time course of residual effects of insomnia medications using a sleep-restriction 
protocol approximating real-life circumstances and assessing the time course of residual effects. 
Previous studies assessing next-day effects of eszopiclone allowed at least 8 hours of sleep 9, 13.  
Whether a similar residual effect profile would be observed if a sleep period of 8 hrs was allowed 
in a study with primary insomnia patients, is unclear as healthy volunteers are typically more 
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sensitive to residual effects.  In addition, subtle deficits in cognitive performance have been 
observed in insomnia patients, particularly attention based tasks with high cognitive load 21 and 
therefore a complex interaction between performance enhancement and residual impairment may 
occur in patient populations.  
 
The AE profile of eszopiclone in this study is consistent with previous findings in healthy 
volunteers and patients with primary insomnia 9. The incidence of specific AE was similar 
between eszopiclone and zopiclone. No new safety or tolerability findings were noted. 
 
In summary, previous research has shown that eszopiclone is an effective hypnotic medication on 
short or long-term administration with no evidence of tolerance.  This study is the first to 
examine the time course of the residual effect profile of eszopiclone, zopiclone and placebo 
following a sleep restriction protocol.  The study showed that both eszopiclone (3 mg) and 
zopiclone (3.75 mg eszopiclone) compared with placebo caused statistically and clinically 
relevant next-day residual effects that continued for several hours after awakening. The data 
indicated these effects were typically smaller in magnitude for eszopiclone, and did not persist to 
the same extent, although these may have been a function of the smaller dose of eszopiclone.  
As with many hypnotics, however, patients should be cautious when driving a vehicle, or 
operating machinery the day after ingestion.  
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Figure 1. CTT Mean Tracking Error:  
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Figure 2. 1-Back and 3-Back Memory Tests: Percentage of Correct Responses.  
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Figure 3. Post Hoc Analysis of Standardised Differences.  
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Table 1. Adverse Events Reported During Double-Blind Treatment (Night 2 Through 
Midnight on Day 3). Adverse events reported in ≥2% of participants with any treatment in 
the ITT population are listed. 
 
 Eszopiclone 
(n=88) 
Racemic Zopiclone 
(n=90) 
Placebo 
(n=89) 
N (%) 
Dysgeusia 27 (31) 30 (33) 0 (0) 
Somnolence 11 (13) 7 (8) 1 (1) 
Fatigue 6 (7) 6 (7) 4 (4) 
Nausea 4 (5) 4 (4) 3 (3) 
Dizziness 4 (5) 5 (6) 0 (0) 
Headache 2 (2) 2 (2) 2 (2) 
Disturbance in attention 2 (2) 3 (3) 0 (0) 
Hallucination 2 (2) 0 (0) 0 (0) 
Nightmare 2 (2) 0 (0) 0 (0) 
Rash 2 (2) 0 (0) 0 (0) 
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Figure Legends 
 
Figure 1.  Adjusted means (SEM) for CTT mean tracking error in pixels (untransformed data). 
Data for the placebo and zopiclone condition were displaced along the x-axis to avoid data points 
being obscured.  Values plotted at the mean time point are the primary endpoint and reflect the 
mean of the first 5 time points post dose.   
 
Figure 2. Adjusted means (SEM) for N-back percentage correct at each time point on Day 3 on 
the 1-back task (panel A) and the 3-back task (panel B) (untransformed data). Placebo (), 
eszopiclone 3 mg (○) and zopiclone 7.5 mg (▼). 
 
Figure 3. Early-morning, middle-morning, and late-morning standardised differences (95% CIs) 
between eszopiclone (○) and placebo, and racemic zopiclone (●) and placebo for secondary 
endpoints. A standardised difference <0 reflects impairment of waking performance following 
treatment compared with placebo. The more negative the standardized difference the greater the 
impairment.  A standardized difference of 0.2 – 0.5 reflects a small size effect, 0.5 – 0.8 a 
medium effect and >0.8 a large effect size.  Significance cannot be determined from whether or 
not 0 is included within the CI.  
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